Dharminder Chahal
CEO
DC Prime
Romania
Biography
Mr. Chahal is a supervisory board member of BioInvent, Sweden, a supervisory board member of VitalneXt, an advisory board member of BioGeneration Ventures II, Thuja Capital Fund I as well as Gilde Healthcare Funds II and III, and observer on the supervisory board of Innate Pharma, France. Mr. Chahal has built an extensive network in the life science industry and a strong track record in direct involvement of complex corporate transactions including the sale of the stake of Van Herk Investments in Crucell to Johnson and Johnson, the sale of deVGen to Syngenta and the sale of Octoplus to Dr. Reddy’s. As a board member or advisor he has been and still is active for several European companies in the field of life sciences.
Research Interest
Business Economics
